FBXW12, a member of the F-box protein family, stands as a pivotal player in cellular regulatory networks, particularly as a critical component of the Skp1-Cullin1-F-box (SCF) E3 ubiquitin ligase complex. The primary function of FBXW12 lies in its role as a substrate recognition module within this complex, orchestrating the targeted degradation of specific proteins through the ubiquitin-proteasome system. This ubiquitin-mediated protein degradation is a fundamental cellular mechanism for maintaining homeostasis, regulating the abundance of proteins crucial for diverse cellular processes. FBXW12, with its F-box domain, interacts with Skp1 and Cul1 to form the SCF complex, conferring specificity to substrate recognition. Its substrate specificity is determined by the interaction of the F-box domain with phosphorylated residues on target proteins, marking them for ubiquitination and subsequent degradation. The intricacies of FBXW12-mediated protein degradation extend to its involvement in various cellular processes, including cell cycle progression, DNA damage response, and signal transduction pathways. By selectively targeting proteins involved in these processes, FBXW12 exerts control over the timing and intensity of cellular responses to internal and external cues. The modulation of FBXW12 activity becomes crucial in instances where aberrant protein turnover may contribute to pathological conditions. Consequently, understanding the mechanisms governing FBXW12 function and its inhibition becomes paramount for unraveling the complexity of cellular regulatory networks.
Inhibition of FBXW12 involves targeted disruptions aimed at impeding its role in substrate recognition and subsequent ubiquitination. Chemical inhibitors strategically intervene at different points in the regulatory network governing FBXW12. For instance, inhibitors like MLN4924 disrupt the NEDDylation pathway, indirectly inhibiting FBXW12 by preventing the modification of substrates critical for its recognition. Proteasome inhibitors, such as MG-132, interfere with the downstream degradation process by blocking the proteasomal machinery, resulting in the accumulation of FBXW12 substrates. Moreover, compounds like JQ1, a bromodomain and extraterminal (BET) protein inhibitor, modulate chromatin accessibility, influencing the transcriptional regulation of genes involved in the control of FBXW12 expression. These diverse mechanisms of inhibition emphasize the complexity of cellular regulatory networks and highlight FBXW12 as a crucial node in the dynamic interplay between protein degradation, signal transduction, and cellular homeostasis.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
NEDD8-activating enzyme (NAE) inhibitor disrupting the NEDDylation pathway. By preventing the NEDDylation of substrates, it indirectly inhibits FBXW12, a substrate recognition component of the SCF E3 ubiquitin ligase complex involved in targeted protein degradation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Proteasome inhibitor disrupting the ubiquitin-proteasome system. Impairs the degradation of SCF E3 ligase substrates, including FBXW12, by preventing their ubiquitination and subsequent proteasomal degradation, thereby indirectly inhibiting FBXW12 activity. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
Inhibitor of MDM2-p53 interaction influencing the p53 pathway. Alters the expression of FBXW12 indirectly by modulating p53-dependent transcription, affecting the regulation of FBXW12 at the transcriptional level. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
Bromodomain and extraterminal (BET) protein inhibitor. Modulates chromatin accessibility and influences FBXW12 indirectly by impacting the transcriptional regulation of genes involved in the control of its expression. | ||||||
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
PDK1 inhibitor affecting the PI3K/AKT pathway. Alters AKT-dependent signaling cascades and indirectly influences FBXW12 by modulating processes related to its post-translational regulation and stability. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $57.00 $184.00 $867.00 | 10 | |
GSK-3 inhibitor impacting the Wnt signaling pathway. Indirectly modulates FBXW12 expression by influencing the activity of GSK-3, a key regulator of the β-catenin pathway that intersects with the regulatory network of FBXW12. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
Thymidylate synthase inhibitor affecting nucleotide synthesis. Indirectly influences FBXW12 expression by disrupting cellular processes dependent on nucleotide availability, thereby impacting the transcriptional regulation of FBXW12. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor impeding protein degradation. Alters the turnover of SCF E3 ligase substrates, including FBXW12, by preventing their ubiquitin-dependent degradation, leading to indirect inhibition of FBXW12 activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor affecting the MAPK pathway. Alters downstream signaling cascades and indirectly impacts FBXW12 expression by modulating the activity of the MAPK pathway, a regulatory network intersecting with FBXW12-mediated protein degradation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
RAF and VEGFR inhibitor influencing multiple signaling pathways. Indirectly modulates FBXW12 expression by affecting the activity of RAF kinases, key components of signaling networks converging on FBXW12-mediated protein degradation. |